TroVax
TroVax is a cancer vaccine that was developed by Oxford BioMedica. No cancer vaccines have been proven to cure cancer or extend life yet, TroVax has been studied in a number of trials for colon cancer.
TroVax uses a tumor-associated antigen, 5T4, with a pox virus vector. 5T4 is found in a wide range of solid cancers and its presence is correlated with poor prognosis.
Research
All solid tumors where the 5T4 tumor antigen is present. Clinical development is ongoing in renal [cell carcinoma], colorectal cancer, lung cancer, and prostate cancer, and is planned in breast cancer.
TroVax is a proprietary tumor-associated antigen, 5T4, delivered by the pox virus vector, modified vaccinia virus Ankara.
Renal cell carcinoma
Trovax is administered in combinations with interleukin-2, interferon-alpha, sunitinib to combat advanced or metastatic renal cell carcinoma to 700 patients, with the primary endpoint being the rate of overall survival. There is a Special Protocol Assessment agreement with the FDA that specifies the design, conduct, analysis and endpoints of the trial.